Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being ...

Cencora is set to invest $1bn by 2030 to expand its US pharmaceutical distribution network, adding resilience and capacity.

Leukogene Therapeutics has received orphan drug designation from the US FDA for M2T-CD33 (LTI-214), its immunotherapy candidate targeting AML.